Artículo
SEOM clinical guideline for the management of malignant melanoma (2017)
Autor/es | Berrocal, A.
Arance, A. Castellón, V. E. Cruz Merino, Luis de la ![]() ![]() ![]() ![]() ![]() ![]() Espinosa, E. Cao, M. G. Larriba, J. L. G. Marquez-Rodas, I. Soria, A. Algarra, S. M. |
Departamento | Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2018 |
Fecha de depósito | 2024-03-12 |
Publicado en |
|
Resumen | All melanoma suspected patients must be con firmed histologically and resected. Sentinel node biopsy
must be done when tumor is over 1 mm or if less with
high-risk factors. Adjuvant therapy with interferon could
be ... All melanoma suspected patients must be con firmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic mel anoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams |
Cita | Berrocal, A., Arance, A., Castellón, V.E., Cruz Merino, L.d.l., Espinosa, E., Cao, M.G.,...,Algarra, S.M. (2018). SEOM clinical guideline for the management of malignant melanoma (2017). Clinical and Translational Oncology, 20 (1), 69-74. https://doi.org/10.1007/s12094-017-1768-1. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
SEOM clinical guideline.pdf | 351.7Kb | ![]() | Ver/ | |